Novo Nordisk’s diabetes pill, Rybelsus, has demonstrated significant cardiovascular benefits in a recent late-stage trial, marking an important development for patients with Type 2 diabetes. Rybelsus is an oral formulation, mostly replacing Novo Nordisk’s famous diabetes injection, Ozempic. It has already received approval to treat Type 2 diabetes. At the American College of Cardiology’s Annual Scientific Session this week in Chicago, a number of important trials were presented. These results reflect an impressive 14% reduction in CV-related complications compared to placebo.
The landmark trial recruited over 9,600 patients 50 years and older. Participants took either Rybelsus or placebo for an average of almost four years. These results show that Rybelsus was able to significantly reduce the risk of cardiovascular death, heart attack, and stroke. The drug was effective in non-fatal heart attacks, reducing the risk by 26%. This significant reduction was instrumental in reducing all-cause cardiovascular events.
As an interesting side note, Rybelsus decreased non-fatal strokes by 12%. Most notably, the treatment reduced deaths from cardiovascular causes by 7% compared to the placebo group. These encouraging results further establish Rybelsus as an exciting new treatment arm for patients. It would make a huge difference for people living with both diabetes and heart disease.
Take the pill without eating. Avoid this within 30 minutes of breakfast and use the minimum amount of water needed. In our study, most patients reported gastrointestinal complaints such as nausea, diarrhea, and constipation as prevalent side effects. These problems did not often lead them to discontinue use of the medication.
“We know not everybody wants an injection, whether it is painful or not; they want the option of an oral medication.” – Gough
To that end, this trial provides strong motivation that patients will adhere to the higher recommended dosage. Consequently, they still have access to the cardiovascular health benefits of Rybelsus.
“Reassurance that patients were able to take the drug as directed and reap cardiovascular health benefits from it,” – Dr. Darren McGuire